Leustatin

Leustatin is a brand name of cladribine, approved by the FDA in the following formulation(s):

LEUSTATIN (cladribine - injectable; injection)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: February 26, 1993
  
  Strength(s): 1MG/ML ^[RLD][AP]

Has a generic version of Leustatin been approved?

Yes. The following products are equivalent to Leustatin:

cladribine injectable; injection

• 
  Manufacturer: APP PHARMS
  
  Approval date: April 22, 2004
  
  Strength(s): 1MG/ML ^[AP]


• 
  Manufacturer: BEDFORD
  
  Approval date: February 28, 2000
  
  Strength(s): 1MG/ML ^[AP]


• 
  Manufacturer: ONCO THERAPIES LTD
  
  Approval date: October 6, 2011
  
  Strength(s): 1MG/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Leustatin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Leustatin.

See also...

• Leustatin Consumer Information (Wolters Kluwer)
• Leustatin Consumer Information (Cerner Multum)
• Leustatin Advanced Consumer Information (Micromedex)
• Leustatin AHFS DI Monographs (ASHP)
• Cladribine Consumer Information (Wolters Kluwer)
• Cladribine Consumer Information (Cerner Multum)
• Cladribine Intravenous Advanced Consumer Information (Micromedex)
• Cladribine AHFS DI Monographs (ASHP)